Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×

Online ordering will be unavailable from 17:00 GMT on Friday, April 25 until 17:00 GMT on Sunday, April 27 due to maintenance. We apologise for the inconvenience.

  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

3 results

  • Chapter 18 - Embolization for the Management of Uterine Fibroids

  • Edited by Mostafa Metwally, University of Sheffield, Tin-Chiu Li, The Chinese University of Hong Kong
  • Book:
    Modern Management of Uterine Fibroids
    Published online:
    10 October 2020
    Print publication:
    03 December 2020, pp 173-183

  • Summary

    Uterine fibroids are the most common benign tumour in premenopausal women, with a lifetime prevalence of almost 70% in Caucasian women and more than 80% in women of Afro-Caribbean descent. About half of these women experience symptoms, with the most common being menorrhagia, dysmenorrhoea, pressure symptoms and infertility. Whilst hysterectomy is still the most commonly offered and performed operation to treat uterine fibroids, over the last 20 years minimally invasive therapies have been gaining popularity and uterine fibroid embolization is now a mainstream option for most women who wish to preserve their uterus. Since its introduction, a strong body of evidence has built demonstrating safety and efficacy with low rates of complication. Uterine fibroid embolization (UFE) was first described as a treatment for symptomatic leiomyomas in 1995 by Ravina et al. and has proved so popular that in the last year there were over 25,000 uterine fibroid embolization procedures performed worldwide [1].